Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer

Kalaghchi, Bita; Abdi, Robab; Amouzegar‐Hashemi, Farnaz; Esmati, Ebrahim; Alikhasi, Afsaneh

doi:10.7314/apjcp.2016.17.s3.287

Cited by 20 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Roles of cisplatin as a radiosensitizer are also have been evaluated in concurrent chemoradiotherapy investigations. [109][110][111] Combination of other material with low usage of cisplatin concentration is also currently being to further increase the radiosensitization effects on target cancer cells. Cisplatin had been combined with organoselenium compound or gold NPs that results in the achievement of additive effects as well as successful enhancement of radiosensitization.…”

Section: Dovepressmentioning

confidence: 99%

<p>Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams</p>

Sisin¹,

Razak²,

Abidin³

et al. 2020

IJN

View full text Add to dashboard Cite

This study aimed to quantify synergetic effects induced by bismuth oxide nanoparticles (BiONPs), cisplatin (Cis) and baicalein-rich fraction (BRF) natural-based agent on the reactive oxygen species (ROS) generation and radiosensitization effects under irradiation of clinical radiotherapy beams of photon, electron and HDR-brachytherapy. The combined therapeutic responses of each compound and clinical radiotherapy beam were evaluated on breast cancer and normal fibroblast cell line. Methods: In this study, individual BiONPs, Cis, and BRF, as well as combinations of BiONPs-Cis (BC), BiONPs-BRF (BB) and BiONPs-Cis-BRF (BCB) were treated to the cells before irradiation using HDR brachytherapy with 0.38 MeV iridium-192 source, 6 MV photon beam and 6 MeV electron beam. The individual or synergetic effects from the application of the treatment components during the radiotherapy were elucidated by quantifying the ROS generation and radiosensitization effects on MCF-7 and MDA-MB-231 breast cancer cell lines as well as NIH/3T3 normal cell line. Results: The ROS generated in the presence of Cis stimulated the most substantial amount of ROS compared to the BiONPs and BRF. Meanwhile, the combination of the components had induced the higher ROS levels for photon beam than the brachytherapy and electron beam. The highest ROS enhancement relative to the control is attributable to the presence of BC combination in MDA-MB-231 cells, in comparison to the BB and BCB combinations. The radiosensitization effects which were quantified using the sensitization enhancement ratio (SER) indicate the highest value by BC in MCF-7 cells, followed by BCB and BB treatment. The radiosensitization effects are found to be more prominent for brachytherapy in comparison to photon and electron beam. Conclusion: The BiONPs, Cis and BRF are the potential radiosensitizers that could improve the efficiency of radiotherapy to eradicate the cancer cells. The combination of these potent radiosensitizers might produce multiple effects when applied in radiotherapy. The BC combination is found to have the highest SER, followed by the BCB combination. This study is also the first to investigate the effect of BRF in combination with BiONPs (BB) and BC (BCB) treatments.

show abstract

Section: Dovepressmentioning

confidence: 99%

<p>Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams</p>

Sisin¹,

Razak²,

Abidin³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…A recent phase III trial demonstrated that concurrent chemo radiation with cisplatin and gemcitabine followed by adjuvant cisplatin and gemcitabine is significantly superior to chemoradiation with weekly cisplatin alone with regard to progression-free survival and overall survival. However, the toxicity of cisplatin/gemcitabine chemoradiation was found to be unacceptably high in other studies, indicating the need for less toxic regimens to be developed [21][22][23][24][25][26][27][28][29][30][31].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Single-Agent Cisplatin versus Cisplatin and 5 Flouro Uracil Chemotherapy in Cervical Cancer Patients in India

2017

IJCRT

View full text Add to dashboard Cite

Cervical cancer is the most common gynecological cancer in Indian women. We conducted this study to assess whether single-agent Cisplatin was better than Cisplatin and 5 flourouracil chemotherapy in cervical cancer patients in India.The aim was to assess tumor response of weekly injections of single-agent Cisplatin versus Cisplatin and 5 flouro uracil chemotherapy in women with carcinoma cervix with FIGO stages IB2 to IIIB. 54 patients were included in this study who completed the treatment. Disease was assessed prior to treatment by pelvic examination and contrast enhanced MRI of the abdomen and pelvis. Response was assessed 1 month after completion of treatment by physical examination and 3 months after also by MRI. There was a complete response rate of 88% after 3 months in patients getting Cisplatin and 5 flouro uracil chemotherapy compared to response rate of 80% in those getting only Cisplatin. The mean duration of treatment was 60 days. In conclusion, combination chemotherapy with cisplatin and 5 FU along with radiotherapy in patients with locally advanced squamous cell carcinoma of cervix was well tolerated and slightly better than single agent chemotherapy with Cisplatin alone.

show abstract

“…[3][4][5] Studies showed that a response between 80 and 90% is obtained with this treatment. [6][7][8] Survival rates in these patients were reported as between 67 and 83%. [9][10][11] A small group of patients with cervical cancer can be unresponsive to CRT.…”

Section: Introductionmentioning

confidence: 92%

Is Surgical Treatment an Option for Locally Advanced Cervical Cancer in the Presence of Central Residual Tumor after Chemoradiotherapy?

Topuz

Kaban

Küçücük

et al. 2020

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective To evaluate the outcomes of surgical treatment in patients with chemoradiotherapy (CRT)-resistant and locally advanced cervical cancer (LACC). Methods Patients with LACC who underwent surgery due to resistance to CRT between 2005 and 2015 were reviewed retrospectively. Disease-free survival (DFS) and overall survival (OS) related factors were analyzed. Results A total of 23 patients were included in the study and the median age was 51 years old. A total of 14 patients (60.8%) experienced recurrence; among these recurrences, 8 of them were local, 5 were distant, 1 was both distant and local. A total of 9 patients (39%) died. The Median DFS and OS durations were 15 and 32 months, respectively. A total of 17 patients (74%) had undergone simple hysterectomy, 4 (17%) radical hysterectomy, and 2 (9%) total pelvic exenteration. Postoperative grade 3 and 4 complications were seen in 12 patients (52%). Macroscopic tumor presence in the pathology specimen was associated with distant recurrence and positive surgical margins with local recurrence (Log-Rank test p = 0.029 and p = 0.048, respectively). The only factor associated with OS was surgical margin positivity (Log-Rank test p = 0.008). The type of surgery, grades 3 and 4 postoperative complications, brachytherapy, and tumor histology were not associated with recurrence. Conclusion In patients with LACC, hysterectomy is an option in the presence of a central residual tumor after CRT. However, the risk of grades 3 and 4 complications of performed surgery is high. The presence of macroscopic tumor in the pathology specimen and positive surgical margins are poor prognostic factors. The goal of the surgeon should be to achieve a negative surgical margin. It does not seem important if the surgery is simple or radical.

show abstract

Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer

Cited by 20 publications

References 0 publications

<p>Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams</p>

<p>Synergetic Influence of Bismuth Oxide Nanoparticles, Cisplatin and Baicalein-Rich Fraction on Reactive Oxygen Species Generation and Radiosensitization Effects for Clinical Radiotherapy Beams</p>

Evaluation of Single-Agent Cisplatin versus Cisplatin and 5 Flouro Uracil Chemotherapy in Cervical Cancer Patients in India

Is Surgical Treatment an Option for Locally Advanced Cervical Cancer in the Presence of Central Residual Tumor after Chemoradiotherapy?

Contact Info

Product

Resources

About